| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | KRYS | Common Stock | Sale | -$7.05M | -100K | -66.67% | $70.50 | 50K | Dec 10, 2021 | By trust | F1, F2, F3 |
| holding | KRYS | Common Stock | 1.85M | Dec 10, 2021 | Direct | ||||||
| holding | KRYS | Common Stock | 1.8M | Dec 10, 2021 | By spouse | F4 |
| Id | Content |
|---|---|
| F1 | On December 3, 2021, Krystal Biotech, Inc. (the "Company"), closed the previously announced underwritten public offering of 2,666,667 shares of its common stock, at a public offering price of $75.00 per share. The Company and certain selling stockholders granted the underwriters a 30-day option to purchase up to an additional 400,000 shares of the Company's common stock offered in the public offering, which includes up to 200,000 shares from the selling stockholders. The underwriters exercised the option and on December 10, 2021, purchased the 400,000 shares of the Company's common stock, including 100,000 shares of the Company's common stock from the Krishnan Family Trust, a selling stockholder. |
| F2 | Directly beneficially owned by the Krishnan Family Trust. The reporting person and his spouse are each joint beneficial owners of the trust with joint voting and investment control. |
| F3 | Prior to the reported transaction, the Krishnan Family Trust held 112,162 shares. In connection with the reported transaction, 18,919 shares were transferred to the Krishnan Family Trust from the reporting person's individual account and 18,919 shares were transferred to the Krishnan Family Trust from Suma Krishnan's, the reporting person's spouse, individual account. |
| F4 | Directly beneficially owned by Suma Krishnan, the spouse of the reporting person. |